Please use this identifier to cite or link to this item:
|Title:||Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma.|
|Authors:||Ng, Steven;Butzkueven, Helmut;Kalnins, Renate M;Rowe, Christopher C|
|Affiliation:||Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia. firstname.lastname@example.org|
|Citation:||Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia 2007; 14(11): 1126-9|
|Abstract:||Primary central nervous system lymphoma (PCNSL) can be associated with preceding demyelinating pseudotumoral brain lesions. The 'sentinel' demyelinating lesions recede spontaneously or with corticosteroid, and are followed by development of PCNSL typically within 12 months. This report describes a 29 year-old post-partum woman who developed PCNSL 4 years after a biopsy-proven pseudotumoral demyelinating episode. She presented with focal seizures in February 2005. She subsequently developed hemiparesis and raised intracranial pressure. MRI showed two contrast enhancing lesions in the right frontal lobe, which were hypermetabolic on (18)F-FDG PET. A provisional diagnosis of tumefactive multiple sclerosis was made. Symptoms recurred despite multiple courses of high dose corticosteroid. Brain biopsy confirmed large B-cell non-Hodgkin's lymphoma. This patient illustrates the importance of considering PCNSL in patients presenting with a space-occupying lesion, even with previously confirmed demyelination, and that the interval between the two events may be several years.|
|Internal ID Number:||17890092|
Brain Neoplasms.complications.pathology.radionuclide imaging
Lymphoma, B-Cell.complications.pathology.radionuclide imaging
Lymphoma, Non-Hodgkin.complications.pathology.radionuclide imaging
Magnetic Resonance Imaging
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.